A new analysis of more than 43,000 adults suggests that GLP-1 drugs, known for weight loss, may also lower blood pressure. Researchers presented the findings at the European Congress on Obesity in May 2026.
The meta-analysis examined 32 phase 3 clinical trials. The average participant was 54 years old, and about 59% had high blood pressure at the start of the study. Participants took GLP-1 medications for an average of about 15 months.
The study found that for every 1% of body weight lost, participants saw a decrease in their systolic blood pressure, which is the upper number in a reading. The more weight someone lost, the more their blood pressure dropped. This link held true regardless of the study length, starting weight, sex, or diabetes status.
Weight loss and blood pressure
Excess weight is known to be linked to high blood pressure. This analysis helps measure that link in the context of GLP-1 drugs. A 2024 analysis of three large trials found that semaglutide, the active ingredient in Ozempic and Wegovy, lowered the upper blood pressure number compared to a placebo. The results were consistent even in people who already had high blood pressure.
A separate 2024 review of 15 trials found similar blood pressure improvements alongside weight loss in people taking GLP-1 drugs. A 2023 analysis of 61 clinical trials found that semaglutide produced the greatest blood pressure reduction of any medication studied.
Beyond weight
Researchers noted that these drugs may directly relax blood vessels, improve kidney salt handling, and reduce stress signals in the body, even without weight loss. These actions can independently lower blood pressure. This suggests GLP-1 drugs and newer multi-hormone medications, called MHRMs, may lower blood pressure through two paths: one related to weight loss and one that acts directly on the cardiovascular and kidney systems.
This second path is still under study. Its existence may explain why some patients see blood pressure benefits that seem larger than what weight loss alone would cause. The newer MHRMs target multiple hormone receptors at once, and researchers are working to understand which mechanisms drive which effects.
Relevance for patients
Obesity and high blood pressure often occur together and reinforce each other. Clinical guidelines already support managing overweight and obesity as a central strategy for lowering blood pressure. For the 59% of trial participants with high blood pressure, the blood pressure lowering effect of these drugs was a meaningful outcome. For people taking these drugs mainly for weight loss, understanding this cardiovascular effect adds important context.
This is especially relevant given how often obesity and metabolic issues overlap. Visceral fat carries risks beyond the cardiovascular system, which underscores why treating obesity matters. For some groups, such as those using GLP-1 drugs during perimenopause, the cardiovascular benefits add another layer of relevance.
Limitations and next steps
The analysis has limitations. It relied on trial-level data, not individual patient data. There was variability across trials in populations and study design. Blood pressure was not the main outcome in any of the included trials. Patients may have also changed their blood pressure medications, which could have affected results.
Several trials are underway to investigate these effects further. Studies in humans are looking at the acute effects of these drugs on heart and blood vessel function, kidney physiology, and neurohormonal pathways.
The consistency of findings across 32 trials and more than 43,000 participants is hard to dismiss. GLP-1 drugs and next-generation obesity medications are already changing how weight management is viewed. This new analysis adds another dimension, suggesting they may also be useful tools for blood pressure management. This is particularly relevant for the large number of people living with both obesity and high blood pressure.
